Dermatology Times: April 13, 2025

123456789101112131415
Across
  1. 5. Brand behind the first OTC eczema lotion with microbiome-friendly certification
  2. 6. Type of debridement found to be faster than autolytic in severe wounds
  3. 7. Subcutaneous form of this drug showed improved plaque psoriasis outcomes vs oral
  4. 9. Company behind precision laser innovation validated in a JAAD study
  5. 13. Emerging delivery system targeting sebaceous glands in nodular acne
  6. 14. Abbreviation for organization that awarded seal of acceptance to Codex labs lotion
  7. 15. Alphyn’s investigational hydrogel currently in phase 2b trial for atopic dermatitis
Down
  1. 1. Vasoconstrictor cream shown to reduce erythema in rosacea
  2. 2. Hormonal life stage associated with under-addressed acne in women
  3. 3. Investigational drug showing efficacy in moderate to severe psoriasis
  4. 4. Type of psoriasis with notable disease burden in recent Korean epidemiologic study
  5. 8. JAK inhibitor evaluated for its potential to treat Netherton Syndrome
  6. 10. AI model outperforming others in keloid vs malignancy classification without dermoscopy
  7. 11. Organization renewing WHO partnership to combat corticosteroid misuse globally
  8. 12. Surname of researcher behind a new scale for measuring facial redness